SCHEMBL743790

SCHEMBL743790

CN1[C@@H]2CC[C@H]1C[C@@H](Oc1ccc(-c3ccc4sccc4c3)cn1)C2.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.43

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PIK3CD known ✓ O00329 1/20 0.34
CA12 O43570 6/20 0.43
CA2 P00918 6/20 0.43
CHRNA7 P36544 3/20 0.42
KCNH2 Q12809 3/20 0.42
CYP2D6 P10635 1/20 0.36
ENPP1 P22413 1/20 0.35
ATM Q13315 1/20 0.34
ATR Q13535 1/20 0.34
DGAT1 O75907 1/20 0.34
NAAA Q02083 1/20 0.34
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743791 1.00 CA12 (0.43) CA12CA2CHRNA7KCNH2CYP2D6
SCHEMBL745008 0.88 CHRNA7 (0.53) CA12CA2CHRNA7KCNH2ENPP1
SCHEMBL745007 0.88 CHRNA7 (0.53) CA12CA2CHRNA7KCNH2ENPP1
SCHEMBL746275 0.84 CHRNA7 (0.42) CA12CA2CHRNA7KCNH2CYP2D6
SCHEMBL743792 0.79 CA12 (0.43) CA12CA2CHRNA7KCNH2ENPP1
SCHEMBL743794 0.76 CHRNA7 (0.42) CHRNA7KCNH2CYP2D6PIK3CD
SCHEMBL744608 0.75 CHRNA7 (0.42) CHRNA7KCNH2CYP2D6PIK3CDNAAA
SCHEMBL747739 0.74 PIK3CD (0.38) CHRNA7CYP2D6ATMATRPIK3CD
SCHEMBL745762 0.73 CHRNA7 (0.53) CHRNA7KCNH2
SCHEMBL745763 0.73 CHRNA7 (0.53) CHRNA7KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-B1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBVIE BAHAMAS LTD (BS) 2014-08-27 EP disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 PIK3CD 543/4885CA12 454/4885CA2 1714/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 PIK3CD 543/4885CA12 454/4885CA2 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.